Request Information
Request Information
The MONARCH® Platform integrates the latest advancements in robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform to improve outcomes and reduce cost.
Listen to Dr. Paul Chomiak share his experience incorporating the MONARCH® Platform into his thoracic surgery practice.
Dr. Fred Moll, a leader and pioneer in the field of medical robotics, founded Auris Health with a vision to transform medical intervention. Johnson & Johnson (J&J) acquired Auris Health in 2019 & Verb Surgical in 2020 to accelerate innovation in the robotics space.
As part of the J&J Family of Companies, Auris is collaborating with the Lung Cancer Initiative that leverages J&J's collective expertise to change the trajectory of lung cancer.
Lung cancer is the # 1 cancer killer – claiming more victims each year than breast, colon and prostate cancers combined. During the early stage of lung cancer, diagnosing small, peripheral nodules safely can be very difficult. Auris' goal is to help physicians overcome the challenges they face when biopsying small, peripheral lung nodules.
The Impact of Monarch® Platform
The MONARCH® Platform integrates a variety of technologies designed to empower physicians with greater reach, uninterrupted vision, and meticulous control. The MONARCH Platform maintains vision throughout the procedure, especially during the most critical step - the biopsy.
The Impact of Monarch Robotics
Bronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.